These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 9527715)

  • 41. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.
    Conway EL
    Clin Neuropharmacol; 1998; 21(1):8-17. PubMed ID: 9579280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in pharmacotherapy for decline of memory and cognition in patients with Alzheimer's disease.
    Kumar V; Goldstein MZ; Doraiswamy PM
    Psychiatr Serv; 1996 Mar; 47(3):249-53. PubMed ID: 8820547
    [No Abstract]   [Full Text] [Related]  

  • 43. Adjuvant anticholinesterase therapy for the management of epilepsy-induced memory deficit: a critical pre-clinical study.
    Mishra A; Goel RK
    Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):512-7. PubMed ID: 24890882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Tacrine in Alzheimer's disease].
    López de Munain A
    Rev Neurol; 1997 Jul; 25 Suppl 1():S70-2. PubMed ID: 9280671
    [No Abstract]   [Full Text] [Related]  

  • 45. Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer's dementia.
    Trzepacz PT; Ho V; Mallavarapu H
    Psychosomatics; 1996; 37(3):299-301. PubMed ID: 8849507
    [No Abstract]   [Full Text] [Related]  

  • 46. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".
    Cutler NR; Sramek JJ
    Alzheimer Dis Assoc Disord; 1995; 9(3):139-45. PubMed ID: 8534412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease.
    Riekkinen P; Riekkinen M
    Neuropsychopharmacology; 1999 Apr; 20(4):357-64. PubMed ID: 10088136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Tacrine: progress in treatment of Alzheimer's disease?].
    Kurz A; Marquard R; Mösch D
    Z Gerontol Geriatr; 1995; 28(3):163-8. PubMed ID: 7664190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic trials using tacrine and other cholinesterase inhibitors.
    Gamzu ER; Thal LJ; Davis KL
    Adv Neurol; 1990; 51():241-5. PubMed ID: 2403716
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
    Lyketsos CG; Corazzini K; Steele CD; Kraus MF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease.
    Samuels SC; Davis KL
    Drug Saf; 1997 Jan; 16(1):66-77. PubMed ID: 9010644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tacrine therapy for the dementia of Alzheimer's disease.
    Manning FC
    Am Fam Physician; 1994 Sep; 50(4):819-26. PubMed ID: 8079912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
    Smith F
    J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical heterogeneity: responders to cholinergic therapy.
    Eagger SA; Harvey RJ
    Alzheimer Dis Assoc Disord; 1995; 9 Suppl 2():37-42. PubMed ID: 8534422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic Potential of Multifunctional Tacrine Analogues.
    Przybyłowska M; Kowalski S; Dzierzbicka K; Inkielewicz-Stepniak I
    Curr Neuropharmacol; 2019; 17(5):472-490. PubMed ID: 29651948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The therapeutic potential of tacrine.
    Kurz A
    J Neural Transm Suppl; 1998; 54():295-9. PubMed ID: 9850938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
    Sjögren M; Hesse C; Basun H; Köl G; Thostrup H; Kilander L; Marcusson J; Edman A; Wallin A; Karlsson I; Troell M; Wachtmaister G; Ekdahl A; Olofsson H; Sandström A; Andreasen N; Minthon L; Blennow K
    J Neural Transm (Vienna); 2001; 108(4):451-8. PubMed ID: 11475012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can we do better in developing new drugs for Alzheimer's disease?
    Gauthier S; Scheltens P
    Alzheimers Dement; 2009 Nov; 5(6):489-91. PubMed ID: 19896588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment.
    Minarini A; Milelli A; Tumiatti V; Rosini M; Simoni E; Bolognesi ML; Andrisano V; Bartolini M; Motori E; Angeloni C; Hrelia S
    Neuropharmacology; 2012 Feb; 62(2):997-1003. PubMed ID: 22032870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tacrine improves working memory deficit caused by permanent occlusion of bilateral common carotid arteries in rats.
    Murakami Y; Tanaka E; Sakai Y; Matsumoto K; Li HB; Watanabe H
    Jpn J Pharmacol; 1997 Dec; 75(4):443-6. PubMed ID: 9469652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.